

Quarter 4: Performance of Initiating (1st April 2020 - 31st March 2021)																											
ID	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	First Patient Recruited?	Date of First Patient Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Patient Recruited	Duration between Date Site Selected and First Patient Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	A - Permissions delayed / denied	B - Suspended by sponsor	C - Closed by sponsor	D - Sponsor Delays	E - Staff availability issues	F - No patients seen	G - No patients consented	H - Contracting delays	I - Rare diseases	J - Other	Comments	Reasons for delay correspond to:
176584	18/LO/0660	237150	REMAP-CAP	Yes	22/06/2020	11	31	42	01/05/2020	11/05/2020	23/07/2018	19/05/2020	22/05/2020	Please Select...	04/06/2020												Please Select...
176585	20/NE/0171	279531	GO41854- Atezolizumab plus Tiragolumab vs Durvalumab in NSCLC	No		51			28/07/2020	04/09/2020	04/09/2020	23/10/2020	25/10/2020	Please Select...	26/10/2020						Y						Neither
176586	20/LO/0790	280190	ARAMIS Rollover Study	Yes	24/02/2021	85	34	119	29/09/2020	28/10/2020	30/06/2020	28/10/2020	21/01/2021	Please Select...	16/02/2021												Please Select...
176706	20/NE/0200	283871	GO41892- Atezolizumab and Cabozantinib vs Docetaxel alone in NSCLC	No		56			14/08/2020	04/01/2021	25/09/2020	01/03/2021	01/03/2021	Please Select...	05/03/2021						Y						Neither
176707	20/LO/1128	288114	Risankizumab v Ustekinumab for Subjects with Crohn's Disease	No		7			22/09/2020	24/02/2021	03/12/2020	09/11/2020	03/03/2021	Please Select...	22/03/2021						Y						Neither
176708	19/WM/0304	268511	Defining the Denominator	Yes	16/02/2021	1	5	6	20/01/2021	10/02/2021	29/01/2020	10/02/2021	11/02/2021	Please Select...	15/02/2021												Please Select...